Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Heritability of caffeine pharmacokinetics and cytochrome P450 1A2 (CYP1A2) activity is controversial. Here, we analyzed the pharmacokinetics of caffeine, an in vivo probe drug for CYP1A2 and arylamine N‐acetyltransferase 2 (NAT2) activity, in monozygotic (MZ) and dizygotic (DZ) twins. In the entire group, common and unique environmental effects explained most variation in caffeine area under the curve (AUC). Apparently, smoking and hormonal contraceptives masked the genetic effects on CYP1A2 activity. However, when excluding smokers and users of hormonal contraceptives, 89% of caffeine AUC variation was due to genetic effects and, even in the entire group, 8% of caffeine AUC variation could be explained by a CYP1A1/1A2 promotor polymorphism (rs2470893). In contrast, nearly all of the variations (99%) of NAT2 activity were explained by genetic effects. This study illustrates two very different situations in pharmacogenetics from an almost exclusively genetic determination of NAT2 activity with no environmental modulation to only moderate genetic effects on CYP1A2 activity with strong environmental modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classical twin studies and beyond
Boomsma, D., Busjahn, A., & Peltonen, L. (2002) · Nature Reviews Genetics · doi:10.1038/nrg932 · Cited by 1,105
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241
Cornelis, M. C., Monda, K. L., Yu, K., Paynter, N., Azzato, E. M., Bennett, S. N., Berndt, S. I., Boerwinkle, E., Chanock, S., Chatterjee, N., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002033 · Cited by 228
Hein, D. W., & Doll, M. A. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.122 · Cited by 121
Cited by
The clinical toxicology of caffeine: A review and case study
Willson, C. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.11.002 · Cited by 289
Let’s talk about sex: Differences in drug therapy in males and females
Madla, C. M., Gavins, F. K. H., Merchant, H. A., Orlu, M., Murdan, S., & Basit, A. W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.014 · Cited by 167
Grzegorzewski, J., Bartsch, F., Köller, A., & König, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752826 · Cited by 108
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Coffee with High but Not Low Caffeine Content Augments Fluid and Electrolyte Excretion at Rest
Seal, A. D., Bardis, C. N., Gavrieli, A., Grigorakis, P., Adams, J. D., Arnaoutis, G., Yannakoulia, M., & Kavouras, S. A. (2017) · Frontiers in Nutrition · doi:10.3389/fnut.2017.00040 · Cited by 55
Biological sex differences in pharmacokinetics and adverse drug reactions
Aljohmani, A., & Yildiz, D. (2026) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04721-8 · Cited by 35
Sex‐Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans
Blöcher, J. A., Meyer‐Tönnies, M. J., Morof, F., Rönnpagel, V., Bethmann, J., Vollmer, M., Engeli, S., & Tzvetkov, M. V. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3454 · Cited by 16
“35,36 Furthermore, CYP1A2 expression and activity are known to increase with tobacco smoking.”
Self-citation
Metadata
- Authors
- Matthaei, J., Tzvetkov, M., Strube, J., Sehrt, D., Sachse‐Seeboth, C., Hjelmborg, J., Möller, S., Halekoh, U., Hofmann, U., Schwab, M., Kerb, R., & Brockmöller, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-09-23
- Volume
- 100
- Issue
- 6
- Pages
- 606-616
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2511206446
- Cited by
- 38
- References
- 6
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.